Introduction {#s1}
============

The WRKY family is regarded as one of the 10 largest transcription factor families in higher plants and has been found throughout the green plant lineage (green algae and land plants) ([@CIT0030]). The WRKY transcription factor family in *Arabidopsis thaliana* contains 74 members, which are divided into three subfamilies according to the number of WRKY domains and category of zinc-finger, forming integral parts of signalling webs that modulate many plant processes by means of modification of the expression patterns of WRKY genes and/or changes in their activity ([@CIT0010]; [@CIT0022], [@CIT0024]; [@CIT0006]). The defining feature of WRKY transcription factors is their DNA-binding domain, which is the almost invariant WRKY amino acid sequence at the N-terminus ([@CIT0023]; [@CIT0009]). The conservation of the WRKY domain is mirrored by a remarkable conservation of its cognate binding site, the W-box (TTGACY) ([@CIT0023]; [@CIT0009]). However, the binding site preferences are also partly determined by additional adjacent DNA sequences outside of the TTGACY core motif ([@CIT0007]; [@CIT0004]).

WRKY transcription factors play an important role in the response of plants to both biotic and abiotic stress and many developmental processes. The function and molecular mechanisms of WRKY transcription factors in biotic stress such as wounding and pathogen infection have been well studied to date. In particular, WRKY factors are key regulators, both positive and negative, of the two partly interconnected branches of plant innate immunity, microbe- or pathogen-associated molecular pattern-triggered immunity and effector-triggered immunity ([@CIT0017]; [@CIT0010]; [@CIT0022]). In regard to abiotic stress, various WRKY transcription factors have been reported to be implicated in drought, cold, and thermo stress tolerance in plants ([@CIT0006]; [@CIT0024]).

Abscisic acid (ABA) is an essential hormone in the regulation of plant growth and development, and in the control of plant adaptation to environmental challenges (reviewed in [@CIT0013]; [@CIT0001]; [@CIT0015]). In the past decades, numerous ABA signalling components, including ABA receptors, have been identified (for reviews, see [@CIT0013]; [@CIT0008]; [@CIT0015]), although many key processes of the highly complex ABA signalling network remain largely unknown. WRKY transcription factors have been suggested to play important roles in ABA signalling pathways ([@CIT0016]; [@CIT0021]; [@CIT0026]; [@CIT0005]; [@CIT0006]; [@CIT0024]). In *Arabidopsis*, the expression level of many WRKY transcription factors can be promoted in the presence of exogenous ABA, and some of the WRKY transcription factors have been identified as key components in the ABA signalling pathways ([@CIT0016]; [@CIT0021]; [@CIT0026]; [@CIT0005]; [@CIT0006]; [@CIT0024]).

It is known that one single WRKY gene often responds to several stress signals, and then participates in the regulation of several different physiological processes during which it seems to act disparately as a negative or positive regulator ([@CIT0009]; [@CIT0033]; [@CIT0010]; [@CIT0027]; [@CIT0020]; [@CIT0006]; [@CIT0024]; [@CIT0031]). WRKY proteins may control the complex mechanisms of transcriptional reprogramming via protein--protein interaction and autoregulation or cross-regulation of expression of their genes ([@CIT0033]; [@CIT0027]; [@CIT0022], [@CIT0024]; [@CIT0006]; [@CIT0031]). Previous reports showed that three paralogous WRKY transcription factors, WRKY18, WRKY40, and WRKY60, cooperate to regulate plant defence in *Arabidopsis* in a complex pattern of overlapping, antagonistic, and distinct roles in response to different types of microbial pathogens ([@CIT0033]; [@CIT0027]; [@CIT0031]). The three closely related WRKY proteins can form both homocomplexes and heterocomplexes, and the DNA binding activities were significantly shifted according to the WRKY proteins present in these complexes ([@CIT0033]). It was previously shown that these three WRKY proteins are also involved in ABA signalling, where WRKY40 plays a central role, and function as negative regulators directly downstream of a candidate ABA receptor CHLH/ABAR (Mg-chelatase H subunit/putative ABA receptor) localized to the chloroplast/plastid envelope membrane, and also repress a set of ABA-responsive genes ([@CIT0026]). At the same time, an independent group reported that WRKY40 negatively regulates ABA signalling, which is consistent with the previous findings, although they found that two other paralogues, WRKY18 and WRKY60, may positively regulate ABA signalling ([@CIT0005]). However, it still remains unclear whether and how the three paralogous WRKY transcription factors cooperate to regulate expression of ABA-responsive genes, especially *ABI4* ([@CIT0014]) and *ABI5* ([@CIT0012]), which encode two key components in the ABA-mediated signalling pathways in seed germination and post-germination growth. To address this question is of importance in order to understand the highly complex ABA signalling pathways.

In the present experiments, it was shown that WRKY18 and WRKY60, together with WRKY40, interact with the promoters of *ABI4* and *ABI5* genes, and cooperatively inhibit *ABI4* and *ABI5* expression, and, further, genetic evidence is provided that ABI4 and ABI5 function downstream of WRKY18 and WRKY60 transcription factors in ABA signalling. A working model of cooperation of the three WRKYs in repressing *ABI4* and *ABI5* expression is proposed, in which the three WRKYs antagonize or aid each other in a highly complex manner. These findings help to understand the complex mechanisms of WRKY-mediated ABA signal transduction.

Materials and methods {#s2}
=====================

Plant materials and growth conditions {#s3}
-------------------------------------

*Arabidopsis thaliana* ecotype Columbia (Col-0) were used as wild-type plants. The three *wrky* mutants, *wrky18*, *wrky40*, and *wrky60*, were described in a previous report ([@CIT0026]). Briefly, the *wrky40-1* mutant (named *wrky40* in this report; stock no. ET5883, with the Ler ecotype as background) was obtained from Cold Spring Harbor Laboratory gene and enhancer trap lines, and contains a Ds transposon inserted within the second exon of *WRKY40* (*Arabidopsis* genomic locus tag: At1g80840), and the *wrky18-1* mutant \[named *wrky18* in this report; Arabidopsis Biological Resource Center (ABRC) stock no. SALK_093916\] and *wrky60-1* mutant (named *wrky60* in this report; ABRC stock no. SALK_120706) are T-DNA insertion knockout mutants with a T-DNA insertion within the first exon in the *WRKY18* (At4g31800) and *WRKY60* (At2g25000) genes, respectively. Both *wrky18* and *wrky60* mutants were isolated from the Col-0 ecotype. All three mutants were previously identified as null alleles in their respective genes ([@CIT0033]; [@CIT0026]). The *wrky40-1* mutation was transferred from its background Ler ecotype into the Col-0 ecotype by backcrossing, as previously described ([@CIT0033]; [@CIT0026]). Double and triple mutants were generated by genetic crosses and identified by PCR genotyping. The *abi4-1* mutant (named *abi4* in this report; ABRC stock no. CS8104) was isolated from the Col-0 ecotype ([@CIT0014]). The mutated *abi5* gene in the *abi5-1* mutant (named *abi5* in this report: ABRC stock no. CS8105) was transferred from its background Wassilewskija (Ws) ecotype into the Col-0 ecotype by backcrossing. Double mutants *abi4 wrky18*, *abi4 wrky60*, *abi5 wrky18*, and *abi5 wrky60* were created by crossing.

Plants were grown in a growth chamber at 19--20 °C on Murashige and Skoog (MS) medium (Sigma) at \~80 µmol photons m^--2^ s^--1^, or in compost soil at \~120 µmol photons m^--2^ s^--1^ over a 16h photoperiod.

Protein production of the WRKYs in *E. coli* {#s4}
--------------------------------------------

6×His-tagged proteins of the full-length WRKY40, WRKY18, and WRKY60 were produced in *Escherichia coli* as described previously ([@CIT0026]). Briefly, the cDNAs encoding these proteins were amplified by PCR using the following primer pairs: forward primer 5'-GGAATTCTATGGATCAGTACTC-3' and reverse primer 5'-ACGCGTCGACCTATTTCTCGGTAT-3' for *WRKY40*; forward primer 5'-GGAATTCTATGGACGGTTCTTCGTTTCTC-3' and reverse primer 5'-ACGCGTCGACTCATGTTCTAGATTGCTCC-3' for *WRKY18*; and forward primer 5'-GGAATTCTATGGACTATGATCC CAACACC-3' and reverse primer 5'-ACGCGTCGACTCATGTTCTT GAATGCTCTATC-3' for *WRKY60.* An *Eco*RI restriction site was introduced by the forward primers, and a *Sal*I restriction site by the reverse primers, into the fragments of the full-length open reading frame (ORF) of *WRKY40*, *WRKY18*, and *WRKY60*. The PCR products were digested and cloned into pET48b(+). The cDNA fragments in the plasmids were sequenced to check for errors. The recombinant cDNAs were expressed in *E.coli* BL21 (DE3) (Novagen) strains as 6×His-tagged fusion proteins. The *E. coli* strains containing the expression plasmids were grown at 37 °C in 1 litre of LB medium containing 50 µg ml^--1^ kanamycin until the OD~600~ of the cultures was 0.6--0.8. Protein expression was induced by the addition of isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside to a final concentration of 1mM at 16 °C with 150 rotations min^--1^. After 16h, the cells were lysed and proteins purified on an Ni^2+^-chelating column as described in the pET system manual.

Quantitative real-time PCR {#s5}
--------------------------

Real-time PCR for expression of various genes was performed as previously described ([@CIT0032]; [@CIT0026]) essentially according to the instructions provided for the BioRad Real-Time System CFX96TM C1000 Thermal Cycler (Singapore). The primers used are as follows: forward primer 5'-GGTAACATTGTGCTCAGTGGTGG-3' and reverse primer 5'-AACGACCTTAATCTTCATGCTGC-3' for *Actin2/8* (an internal control); forward primer 5'-GGGCAGGAA CAAGGAGGAAGTG-3' and reverse primer 5'-ACGGCGGTGG ATGAGTTATTGAT-3' for *ABI4* (At2g40220); and forward primer 5'-CAATAAGAGAGGGATAGCGAACGAG-3' and reverse primer 5'-CGTCCATTGCTGTCTCCTCCA-3' for *ABI5* (At2g36270).

Yeast one-hybrid assay {#s6}
----------------------

Yeast one-hybrid assay was performed essentially as previously described ([@CIT0026]) with the kit provided by Clontech (Matchmaker™ One-Hybrid Library Construction & Screening Kit catalogue no. 630304) using the AH109 yeast strain according to the manufacturer's instructions. The related cDNAs or promoter DNAs were amplified by PCR using the following primer pairs: forward primer 5'-TCCCCCGGGGGGTAATTCATGCCACGCTTT-3' and reverse primer 5'-CGACGCGTGGTTGTGTTGATGTTGGGA-3' for the *ABI4* promoter; forward primer 5'-TCCCCCGGGCAGCCGAA CGGATTCTTTGTC-3' and reverse primer 5'-CGACGCGTTCTCA CCACCACCTCCTCCA-3' for the *ABI5* promoter; forward primer 5'-CCGGAATTCATGGATCAGTACTCATCC-3' and reverse primer 5'-CCGCTCGAGCTATTTCTCGGTATGATTC-3' for *WRKY40* cDNA; forward primer 5'-CCGGAATTCATGGACGGTTCTTCGTTTCTC-3' and reverse primer 5'-CCGCTCGAGTCATGTTCTAGATTGCTCC-3' for *WRKY18* cDNA; and forward primer 5'-CCGGAATTCATGG ACTATGATCCCAACACC-3' and reverse primer 5'-CCGCTCGAGTC ATGTTCTTGAATGCTCTATC-3' for *WRKY60* cDNA. The promoter fragments of *ABI4* and *ABI5* were subcloned into the *Sma*I/*Mlu*I sites of the pHIS2 vector. The one-hybrid assays were performed using the AH109 yeast strain according to the manufacturer's instructions. Yeast cells were co-transformed with pHIS2 bait vector that harboured the promoter of target genes and pGADT7 prey vector that carried the ORF of *WRKY40*, *WRKY18*, and *WRKY60.* As negative controls, the yeast cells were transformed with the empty pGADT7 vector with pHIS2 harbouring the corresponding promoter. Transformed yeast cells were first grown in tryptophan (Trp) and leucine (Leu)-deficient SD medium (SD--Trp--Leu) to ensure that the yeast cells were successfully co-transformed, and then the yeast cells were grown on plates of the Trp, Leu, and histidine (His)-deficient SD medium (SD--Trp--Leu--His) supplemented with 3-aminotriazole (3-AT; Sigma) at 25mM (for the pHIS2 vector with the *ABI5* promoter) or 5mM (for the pHIS2 vector with the *ABI4* promoter). The plates were then incubated at 30 °C for 3 d prior to investigations.

Gel shift assay {#s7}
---------------

Gel shift assay (GSA) was performed essentially as previously described ([@CIT0004]; [@CIT0026]) using the recombinant His-WRKY40, His-WRKY18, and His-WRKY60 proteins purified from *E. coli* as described above. The promoter fragments used for the GSA were amplified by PCR using the following primer pairs: forward primer 5'-GACAAAAGATGTTGACCTTC-3' and reverse primer 5'-GGAGAATTTTGACTGAAAGG-3' for the *ABI5* promoter fragment p*ABI5*-I; forward primer 5'-GACAAAAGATGTTCAC CTTC-3' and reverse primer 5'-GGAGAATTTTGAGTGAAAGG-3' for the site-specific mutations of the W-box in the fragment p*ABI5*-I; forward primer 5'-CGTTTGTCGCTGTCACGATGTG-3' and reverse primer 5'-GTCCCTTATTCAACTATCACG-3' for the *ABI5* promoter fragment p*ABI5*-II; forward primer 5'-GTTATTTCAATATTTTTTACG TTATTTAAACTCCACTTTACC-3' and reverse primer 5'-GGTAAAGT GGAGTTTAAATAACGTAAAAAATATTGAAATAAC-3' for the site- specific mutations of the W-box in the fragment p*ABI5*-II; forward primer 5'-CTGAAGTTTGGTCAAAATAA-3' and reverse primer 5'-CA ACTGCATCATATACACAA-3' for the *ABI5* promoter fragment p*ABI5*-III; forward primer 5'-CTGAAGTTTGCTCAAAATAA-3' and reverse primer 5'-CAACTGCATCATATACACAA-3' for the site-specific mutations of the W-box in the fragment p*ABI5*-III; forward primer 5'-CTGTTTTATTCACTTGATCTTC-3' and reverse primer 5'-GAATA TTGCAACATATATAAG-3' for the *ABI4* promoter fragment p*ABI4*-I; forward primer 5'-GTTACAATTTAAATTCACAAGTAC-3' and reverse primer 5'-GTACTTGTGAATTTAAATTGTAAC-3' for site-specific mutations of the W-box in the fragment p*ABI4*-I; forward primer 5'-CCAATGTGTAACAAGTAACTTATG-3' and reverse primer 5'-CTG AAGAGTGTTTGAATGTC-3' for the *ABI4* promoter fragment p*ABI4*-II; and forward primer 5'-CCATTCACAACGATTACATTCAAACACTC TTCAG-3' and reverse primer 5'-CTGAAGAGTGTTTGAATGTAA TCGTTGTGAATGG-3' for site-specific mutations of the W-box in the fragment p*ABI4*-II. The boxed letters in the primer sequences indicate mutated nucleotides.

The site-specific mutations in the core sequence of the p*ABI5*-II and p*ABI4-*II fragments of the promoters were introduced into the above promoters by two independent PCRs. Reconstitution was done using equimolar quantities of the two fragments from the initial PCRs for each promoter, which were used as the template for a third PCR. The mutations were verified by sequence analysis. Each of the promoter fragments was labelled in the base T with digoxigenin-dUTP (Roche, Mannheim, Germany) according to the manufacturer's instructions. Binding reactions were performed in 20 µl of binding buffer composed of 10mM TRIS-HCl (pH 8.0), 20mM NaCl, 0.4mM MgCl~2~, 0.5mM ZnSO~4~, 0.25mM EDTA, 0.25mM dithiothreitol (DTT), and 10% glycerol, and in the presence of 0.04mg ml^--1^ of poly(dI--dC) sodium salt (Sigma). Binding reactions were carried out using 50ng of His-WRKY fusion proteins and 26ng of each of the digoxigenin-labelled promoter fragments at room temperature for 30min. Samples were separated on a 5% denaturing polyacrylamide gel (19:1 acrylamide:bisacrylamide) in 0.25 TRIS-borate-EDTA at 4 °C, transferred onto a nylon filter, exposed under ultraviolet light to cross-link the samples to the filter, washed with SSC buffer twice for 15min each, blocked with blocking reagent (provided in the kit) for 2h, incubated with the anti-digoxigenin-AP (alkaline phosphatase) antibody for 1h before adding the AP substrate into the mixture, and analysed by autoradiography. The WRKY40 protein amounts loaded for the GSA were tested by immunoblotting with both the anti-His serum (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd, China) and an antiserum specifically against WRKY40 that was described previously ([@CIT0026]), and WRKY18 and WRKY60 proteins were assayed using the anti-His serum.

Trans-inhibition of *ABI4* promoter and *ABI5* promoter activity by WRKYs in tobacco leaves {#s8}
-------------------------------------------------------------------------------------------

This assay was performed essentially according to the previously described procedures ([@CIT0026]). WRKY40, WRKY18, and WRKY60 were used for the effector constructs. The cDNAs of the *WRKY* genes were amplified by PCR using the following primer pairs: forward primer 5'-GCTCTAGAATGGATCAGTACTCAT-3' and reverse primer 5'-ACGCGTCGACCTATTTCTCGGTATGA-3' for *WRKY40*; forward primer 5'-GGGGTACCATGGACGGTTCTTCGTTTCTC-3' and reverse primer 5'-ACGCGTCGACTCATGTTCTAGATTGCTCC-3 for *WRKY18*; and forward primer 5'-GCTCTAGAATGGACTAT GATCCCAACACC-3' and reverse primer 5'-ACGCGTCGACTCAT GTTCTTGAATGCTCTATC-3 for *WRKY60*. The PCR products were fused to the pCAMBIA1300-Myc vector downstream of the *Cauliflower mosaic virus* (CaMV) 35S promoter and the Myc tag at the *Xba*I/*Sal*I sites for *WRKY40* and *WRKY60*, and *Kpn*I/*Sal*I sites for *WRKY18*. The reporter constructs were composed of the *ABI5* or *ABI4* promoter linked to the luciferase (*LUC*) gene. The *ABI5* promoter was isolated using the forward primer 5'-GGGGTACCCAGCCGAACGGATTCT-3' and reverse primer 5'-TCCCCCGGGCAACTGCATCATATACAC-3'. The *ABI4* promoter was isolated using the forward primer 5'-GGGGT ACCGGGTAATTCATGCCACGCTTTG-3' and reverse primer 5'-TCC CCCGGGAGATGAAGAAGAAGAAGAAG-3'. The site-specific mutations in the core sequence of *ABI5* and *ABI4* promoters were introduced by two independent PCRs, in which the primers mentioned above together with the primers described earlier in the GSA, including the primers p*ABI5-*I, p*ABI5-*II, and p*ABI4-*II, were used. The *LUC* cDNA was amplified by PCR using the forward primer 5'-TCCCCCGGGATGGAAGACGCCAAAAAC-3' and reverse primer 5'-CGGGATCCTTACACGGCGATCTTTCCGC-3' from the pGL3- Basic Vector harbouring the *LUC* cDNA. The DNAs of the *ABI5* promoter and *ABI4* promoter were separately fused to the *Kpn*I/*Sma*I sites of the pCAMBIA1300 vector from which the CaMV 35S promoter was deleted, with the *LUC* cDNA fused to the *Sma*I/*Bam*HI sites downstream of the *ABI5* promoter or *ABI4* promoter. *Actin2* was isolated using the forward primer 5'-CGG GATCCATGGCTGAGGCTGATGATATTC-3' and reverse primer 5'-CCGCTCGAGTCAATTTGCATGTAAGAGAATTC-3'. The cDNA of *Actin2* was fused to the pBI121 vector downstream of the CaMV 35S promoter at the *Bam*HI/*Xho*I sites, and was used as an internal control. The constructs were mobilized into *Agrobacterium tumefaciens* strain GV3101. Bacterial suspensions were infiltrated into young but fully expanded leaves of 7-week-old *Nicotiana benthamiana* plants using a needleless syringe. It is noteworthy that the amounts of the constructs were the same among treatments and controls for each group of assays. After infiltration, plants were grown first in darkness for 12h and then with 16h light d^--1^ for 60h at room temperature, and the LUC activity was observed with a CCD imaging apparatus (Andor iXon, Andor, UK). For each group of assays, immunoblotting was conducted to test the expression levels of WRKY40, WRKY18, WRKY60, and Actin2 using anti-Myc serum (Medical & Biological Laboratories Co., Ltd, Naka-ku, Nagoya, Japan) and anti-actin serum (Agrisera, Vännäs, Sweden), respectively. Each experiment was repeated independently at least five times with similar results.

Chromatin co-immunoprecipitation (ChIP) {#s9}
---------------------------------------

The ChIP assay was performed using the transgenic complemented *wrky18*/*60* mutants. The *wrky18-1* and *wrky60-1* mutants were complemented by introducing into the mutant plants, respectively, the *WRKY18* and *WRKY60* cDNAs driven by their corresponding native promoters (\~1.3kb for *WRKY18* and \~1.35kb for *WRKY60*) that were amplified by PCR using the following primer pairs: forward primer 5'-AACTGCAGTGCCGACCTACAAATC-3' and reverse primer 5'-ACGCGTCGACATCTTAAGATACAAACCAA-3' for the *WRKY18* promoter; and forward primer 5'-AACTGCAGTTTGCTGC TGTTTCAAG-3' and reverse primer 5'-GCTCTAGAAAATTTAG GTTCACAGGAG-3' for the *WRKY60* promoter. The PCR product of the *WRKY18* or *WRKY60* promoter was fused to the *Pst*I/*Sal*I (for the *WRKY18* promoter) or *Pst*I/*Xba*I sites (for the *WRKY60* promoter) of the pCAMBIA1300-GFP vector from which the CaMV 35S promoter was deleted. The cDNAs of *WRKY18 and WRKY60* were amplified by PCR using the following primer pairs: forward primer 5'-ACGCGTCGACATGGACGGTTCTTCG-3' and reverse primer 5'-CGGGGTACCTCATGTTCTAGATTGC-3' for *WRKY18*; and forward primer 5'-GCTCTAGAATGGACTATGATCC-3' and reverse primer 5'-CGGGGTACCTCATGTTCTTGAATG-3' for *WRKY60*. The cDNA of *WRKY18* was fused to the *Sal*I/*Kpn*I sites downstream of the *WRKY18* promoter, while cDNA of *WRKY60* was fused to *Xba*I/*Kpn*I sites downstream of the *WRKY60* promoter. Two-week-old seedlings were used for the ChIP assay. The procedures of the ChIP assay were essentially the same as described previously ([@CIT0025]; [@CIT0026]) except for the antibodies: in the present experiment, the antibody against green fluorescent protein (GFP; Ythx Biotechnology, Beijing, China) was used to immunoprecipitate the GFP-tagged WRKY18 or WRKY60 which in turn pulled down DNA fragments to which they bind. The results presented here were obtained from at least five independent experiments.

Phenotypic analysis {#s10}
-------------------

Phenotypic analysis was done essentially as previously described ([@CIT0028]; [@CIT0032]; [@CIT0026]). Briefly, to assay germination, seeds (dry seeds \~1 month after harvest) were planted on MS medium (Sigma, St Louis, MO, USA; product \#M5524; full-strength MS) that contained 3% sucrose and 0.8% agar (pH 5.9). The medium was supplemented or not with different concentrations of (±)-ABA. The seeds were incubated at 4 °C for 3 d for stratification, and then placed at 20 °C under light conditions, and germination (emergence of radicals) was scored at the indicated times. Early seedling growth was assessed by directly planting the seeds in the (±)-ABA-containing MS medium. The seeds were incubated at 4 °C for 3 d for stratification, and then placed at 20 °C under light conditions to investigate the response of seedling growth to ABA after germination. Early seedling growth was also investigated by transferring germinating seeds to (±)ABA-containing MS medium as follows: seeds were germinated after stratification on common MS medium, and transferred to MS medium supplemented with different concentrations of (±)-ABA in the vertical position. The time for transfer was \~46h after stratification. Seedling growth was investigated at the indicated times after the transfer, and the length of primary roots was measured using a ruler.

Accession numbers {#s11}
-----------------

Sequence data from this article can be found in the Arabidopsis Genome Initiative database under the following accession nos: At1g80840 (WRKY40), At4g31800 (WRKY18), At2g25000(WRKY60), At2g40220 (ABI4), and At2g36270 (ABI5). Germplasm identification numbers for mutant lines and SALK lines are as follows: *abi4-1* (ABRC stock no. CS8104), *abi5-1* (ABRC stock no. CS8105), *wrky40-1* (stock no. ET5883, Cold Spring Harbor Laboratory gene and enhancer trap lines), *wrky18-1* (ABRC stock no. SALK_093916), and *wrky60-1* (ABRC stock no. SALK_120706).

Results {#s12}
=======

WRKY18, WRKY40, and WRKY60 bind the *ABI4* promoter and cooperatively inhibit its activity {#s13}
------------------------------------------------------------------------------------------

It was previously observed that WRKY40 binds the promoter of the *ABI4* gene ([@CIT0026]), but it still remains unknown whether it regulates *ABI4* expression, and whether WRKY18 and WRKY60 also interact with *ABI4* promoter and regulate its expression. ABI4 belongs to a class of Apetala-2 domain transcription factors ([@CIT0014]), and the *ABI4* gene has, in its promoter region, W-box sequences, a *cis*-regulatory element to which the WRKY transcription factors bind. Interactions of the WRKYs with the *ABI4* promoter were first tested in a yeast one-hybrid system. Yeast cells co-transformed with both a WRKY-encoding cDNA (*WRKY18*, *WRKY40*, or *WRKY60*) and the *ABI4* promoter could grow in a selection SD medium (lacking Trp, Leu, and His nutrients, and containing 3-AT), indicating a potential interaction between the WRKYs and the *ABI4* promoter ([Fig. 1A](#F1){ref-type="fig"}). As a negative control, yeast cells co-transformed with empty vector (pGADT7) and the *ABI4* promoter could not grow in this medium ([Fig. 1A](#F1){ref-type="fig"}), showing that this system was specific for testing protein--promoter interactions. These data suggested that WRKY18 and WRKY60 potentially bind the promoter of *ABI4* ([Fig. 1A](#F1){ref-type="fig"}).

![Interaction of WRKYs with the *ABI4* promoter. (A) Yeast one-hybrid assay. The prey vector harbouring WRKY40, WRKY18, and WRKY60 (indicated by +WRKY18, +WRKY40, and +WRKY60, respectively) and the bait vector pHIS2 harbouring the *ABI4* promoter (indicated by p*ABI4*-pHIS2) were used to co-transform yeast cells. The transformation with the empty vector pGADT7 (indicated by + pGADT7) was taken as a negative control. The experiments were repeated three times with the same results. (B) The promoter structure of the *ABI4* gene. W1, W2, and W3 denote each W-box numbered from left to right with sequence sites relative to the star code. The top bars with the p*ABI4-*1 and p*ABI4-*2 domains indicate the sequence fragments used in the ChIP assay with the antiserum specifically against WRKY40, which was described in a previous report ([@CIT0026]). The bottom bars with the first domain (p*ABI4*-I) and second domain (p*ABI4*-II) indicate the sequence fragments used in the GSAs described in (C) and (D). (C) GSA shows that WRKY18, WRKY40, WRKY60, WRKY18 plus WRKY40 (WRKY18+40), WRKY18 plus WRKY60 (WRKY18+60), WRKY40 plus WRKY60 (WRKY40+60), and WRKY40 plus WRKY18 plus WRKY60 (WRKY40+18+60) all bind the p*ABI4*-I fragment (left panel). The 6×His tag peptide (6His), which was fused to WRKY protein for WRKY protein production, and BSA protein (left panel) and the promoter fragments harbouring the mutated W-box 1 (W1) (right panel), served as negative controls. W-box mutation at W1: TTGAC→TTCAC (see the Materials and methods). The experiments were repeated five times with substantially the same results. (D) GSA shows that WRKY40, WRKY60, WRKY40 plus WRKY18 (WRKY40+18), WRKY18 plus WRKY60 (WRKY18+60), and WRKY40 plus WRKY60 (WRKY40+60) bind the p*ABI4*-II fragment, but WRKY18 and WRKY40 plus WRKY18 plus WRKY60 (WRKY40+18+60) do not (left panel). The 6×His tag peptide (6His), which was fused to WRKY protein for WRKY protein production, and BSA protein and the promoter fragments harbouring the mutated W-boxes 2 and 3 (W2/W3), served as negative controls (right panel). W-box mutations at W2 and W3: TGAC→TTAC (see the Materials and methods). The experiments were repeated five times with substantially the same results. In (C) and (D), loading protein amounts were tested by immunoblotting with anti-6His serum and an antiserum specifically against WRKY40 ([@CIT0026]), and relative band intensities, which are normalized relative to the intensity of the loading sample of the assay with WRKY40 alone (indicated by 100), are indicated by numbers above (for 'WRKY40' bands) or below the bands (for 'Ant-6His' bands).](exbotj_ers293_f0001){#F1}

These protein--promoter interactions were confirmed, and interactions of the WRKYs with two different domains of the *ABI4* promoter were further tested in a GSA, in which one domain (domain I, p*ABI4*-I) covers the first W-box and another covers the second and third W-boxes (domain II, p*ABI4*-II) ([Fig. 1B](#F1){ref-type="fig"}; [Supplementary Table S1](http://jxb.oxfordjournals.org/lookup/suppl/doi:10.1093/jxb/ers293/-/DC1) available at *JXB* online). The three WRKY proteins were produced and purified from *E. coli* ([Supplementary Fig. S1](http://jxb.oxfordjournals.org/lookup/suppl/doi:10.1093/jxb/ers293/-/DC1)), and it was shown that the purified WRKY18, WRKY40, and WRKY60 proteins all bind domain I (p*ABI4*-I) ([Fig. 1C](#F1){ref-type="fig"}). The mixed proteins WRKY18 plus WRKY40, WRKY18 plus WRKY60, WRKY40 plus WRKY60, or all three WRKYs all showed binding activities to this promoter domain ([Fig. 1C](#F1){ref-type="fig"}).

WRKY40 and WRKY60, but not WRKY18, showed binding activities to domain II of the *ABI4* promoter (p*ABI4*-II), and the mixed proteins pairs WRKY18 plus WRKY40, WRKY18 plus WRKY60, or WRKY40 plus WRKY60 also showed binding activities to this promoter domain, while the three mixed WRKYs showed no binding activity to this domain ([Fig. 1D](#F1){ref-type="fig"}), suggesting that the interactions of the three WRKYs with each other affect their binding to this domain. It is noteworthy that a previous report showed the *in vivo* interaction of WRKY40 with the *ABI4* promoter by ChIP via p*ABI4*-I/II domains ([Fig. 1B](#F1){ref-type="fig"}, and see also [@CIT0026]), which is consistent with the data of the present GSA.

As negative controls, neither the binding activity of the WRKYs to the *ABI4* promoter domains harbouring a mutated W-box 1 ([Fig. 1C](#F1){ref-type="fig"}) or mutated W-boxes 2 and 3 ([Fig. 1D](#F1){ref-type="fig"}), nor that of 6×His peptide and bovine serum albumin (BSA) to any domain of the *ABI4* promoter ([Fig. 1C](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}), was observed, showing that the observed binding activities of the WRKYs were specific in this GSA system. Additionally, the loading amounts of the different WRKY proteins in the assays were tested by immunoblotting, which showed that substantially an equal amount of each WRKY protein was loaded in the assays with a single WRKY protein, WRKY18, WRKY40, or WRKY60, while the amounts were equally doubled in the assays with two WRKY proteins, and tripled with three WRKY proteins, indicating that the loss of binding activities of WRKY18 and the mixture of the three WRKYs to the *pABI4*-II domain ([Fig. 1D](#F1){ref-type="fig"}) was specific, but was not caused by a possible difference in protein loading amount.

Next, the interactions of WRKY18 and WRKY60 with the *ABI4* promoter in the same above-mentioned p*ABI4*-I/II domains were assayed by ChIP analysis combined with PCR and quantitative real-time PCR. It was observed that WRKY18 binds to the promoters of *ABI4* via the p*ABI4*-I domain but not the p*ABI4*-II domain, and that WRKY60 binds the promoters of *ABI4* via both the p*ABI4*-I and p*ABI4*-II domains ([Fig. 2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"}; [Supplementary Table S1](http://jxb.oxfordjournals.org/lookup/suppl/doi:10.1093/jxb/ers293/-/DC1) at *JXB* online), which is consistent with the data of the above-described GSA ([Fig. 1B--D](#F1){ref-type="fig"}), and reveals that WRKY18 and WRKY60 interact with the *ABI4* promoter *in vivo*.

![WRKY18 (A and B) and WRKY60 (C and D) interact with the promoters of *ABI4* and *ABI5*: ChIP assay. (A and C) PCR data from the ChIP assay. In the promoter fragment names, the prefix 'p' indicates promoter. The sequences for each promoter fragment (indicated by the suffix number) are indicated in [Fig. 1B](#F1){ref-type="fig"} (for *ABI4*) and [Fig. 5B](#F5){ref-type="fig"} (for *ABI5*). In, PCR product from the chromatin DNA; --, PCR product from ChIP with pre-immune serum (as a negative control); +, PCR product from ChIP with the antibody against green fluorescent protein (GFP) which was used to tag WRKY18 and WRKY60 to express the fusion proteins in the *wrky18* and *wrky60* knockout mutants, respectively, and ChIP assays were performed with these transgenic mutant plants. (B) and (D) Real-time PCR data from the ChIP assay with the antibody against GFP and with the *Actin* promoter (p*ACTIN*) as a negative control. All the symbols for promoters present the same significances as described in (A) and (C). Each value in (B) and (D) is the mean ±SE of five independent determinations, and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test).](exbotj_ers293_f0002){#F2}

Furthermore, the interactions of WRKYs with the *ABI4* promoter were assayed in an *in vivo* system by co-transforming tobacco leaves with the *WRKY* genes and the *ABI4* promoter linked to LUC. The results showed that all the three WRKYs interact with the *ABI4* promoter *in vivo*, and WRKY40 and WRKY60 inhibit the promoter activity reported by LUC-produced fluorescence ([Fig. 3A](#F3){ref-type="fig"}). It was observed that co-expression of WRKY18 and WRKY40 suppressed the repressive effect of WRKY40, and co-expression of WRKY40 and WRKY60 partly suppressed the repressive effect of the single WRKY40 or WRKY60 on the *ABI4* promoter activity ([Fig. 3B](#F3){ref-type="fig"}). The co-expression of the three WRKYs completely suppressed the repressive effect of the each single WRKY on the *ABI4* promoter activity ([Fig. 3C](#F3){ref-type="fig"}), which is consistent with the inability of the mixture of the three WRKYs to bind to domain II of the *ABI4* promoter observed in the GSA ([Fig. 1D](#F1){ref-type="fig"}). As internal controls, the Actin2 protein was co-expressed with the *ABI4* promoter--LUC and/or with the WRKYs in a virtually equal amount for each assay, which did not change the activity of *ABI4* promoter--LUC ([Fig. 3D](#F3){ref-type="fig"}) or any observations ([Fig. 3A--C](#F3){ref-type="fig"}), and the expression levels of each WRKY protein, assayed by immunoblotting with the antiserum against their Myc tag, showed no significant difference among them in any assay ([Fig. 3A](#F3){ref-type="fig"}, [3B](#F3){ref-type="fig"}), indicating that the observed differences in the fluorescence intensity were not caused by possible differences in the WRKY levels. These controls showed that the observations of these WRKY--*ABI4* promoter interaction assays are specific and reliable. Additionally and importantly, it was further shown that WRKY40 and WRKY60 did not inhibit the activity of the *ABI4* promoter harbouring W-box 2 and 3 double mutations ([Fig. 4A](#F4){ref-type="fig"}), revealing that the WRKY proteins bind the *ABI4* promoter through the W-box motif.

![Test of the interactions of WRKYs with the *ABI4* promoter *in vivo* in tobacco leaves. Tobacco leaves were transformed with the following constructs together with a control construct harbouring the Actin-encoding open reading frame, called 'K': (A) with p*ABI4*-LUC plus K, p*ABI4*-LUC plus WRKY40 and K, p*ABI4*-LUC plus WRKY18 and K, or p*ABI4*-LUC plus WRKY60 and K; (B) with p*ABI4*-LUC plus K, p*ABI4*-LUC plus WRKY40 and WRKY18 and K, p*ABI4*-LUC plus WRKY18 and WRKY60 and K, or p*ABI4*-LUC plus WRKY40 and WRKY60 and K; (C) with p*ABI4*-LUC plus K, or p*ABI4*-LUC plus WRKY40 and WRKY18 and WRKY60 and K; and (D) with p*ABI4*-LUC alone and p*ABI4*-LUC plus K (as controls). The prefix 'p' indicates promoter. Left panels in (A), (B), (C), and (D): fluorescence imaging. Right panels in (A), (B), (C), and (D): fluorescence intensities estimated by fluorescence counts. The expression levels of the internal control Actin protein (K) and the Myc-tagged WRKY18/WRKY40/WRKY60 protein were assayed by immunoblotting with antiserum against Actin and anti-Myc serum, respectively, and are displayed below the fluorescence count columns. Relative protein band intensities, which are normalized relative to the intensity of the sample from no-transgenic portions (NT) of the same transgenic leaves for K (Actin), or to that of the p*ABI4*-WRKY40 treatment (A) or p*ABI4*-WRKY40+18 treatment (B), are indicated by numbers below the bands. Each value for the columns in the right panels is the mean ±SE of five independent determinations, and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test).](exbotj_ers293_f0003){#F3}

![Test of the interactions of WRKYs with the W-box-mutated *ABI4* and *ABI5* promoters *in vivo* in tobacco leaves. The *ABI4* promoter harbours W-box 2 and 3 double mutations (still named p*ABI4*), and the *ABI5* promoter harbours W-box 1, 2, and 4 triple mutations (still named p*ABI5*). The tobacco leaves were transformed with the following constructs together with a control construct harboring the Actin-encoding open reading frame (K): (A) with p*ABI4*-LUC plus K, p*ABI4*-LUC plus WRKY40 and K, p*ABI4*-LUC plus WRKY18 and K, or p*ABI4*-LUC plus WRKY60 and K; (B) with p*ABI5*-LUC plus K, p*ABI5*-LUC plus WRKY40 and K, p*ABI5*-LUC plus WRKY18 and K, or p*ABI5*-LUC plus WRKY60 and K. Left panels in (A) and (B): fluorescence imaging. Right panels in (A) and (B): fluorescence intensities estimated by fluorescence counts. The expression levels of the internal control Actin protein (K) and the Myc-tagged WRKY18/WRKY40/WRKY60 protein were assayed by immunoblotting with antiserum against Actin and anti-Myc serum, respectively, and are displayed below the fluorescence count columns. Relative protein band intensities, which are normalized relative to the intensity of the sample from no-transgenic portions (NT) of the same transgenic leaves for K (Actin), or to that of the p*ABI4*- (A) or p*ABI5*-WRKY40 treatment (B), are indicated by numbers below the bands. Each value for the columns in the right panels is the mean ±SE of five independent determinations, and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test).](exbotj_ers293_f0004){#F4}

WRKY18, WRKY40, and WRKY60 bind the *ABI5* promoter and cooperatively inhibit its activity {#s14}
------------------------------------------------------------------------------------------

It was previously shown that WRKY40 binds the promoter of *ABI5* and represses its expression ([@CIT0026]), but it still remains unknown whether WRKY18 and WRKY60 interact with the *ABI5* promoter and regulate its expression. ABI5 is a member of the basic leucine zipper transcription factor family ([@CIT0012]), and there are six W-boxes in the promoter region of the *ABI5* gene. The same assays as described above for the *ABI4* promoter was performed to test interactions of WRKYs with the *ABI5* promoter. It was shown that, as previously reported for WRKY40 ([@CIT0026]), the two other WRKY members WRKY18 and WRKY60 interact with the *ABI5* promoter in the yeast one-hybrid system ([Fig. 5A](#F5){ref-type="fig"}). For assaying these protein--promoter interactions by the GSA system, three domains in the *ABI5* promoter were isolated: domain I (p*ABI5*-I) covers the first and second W-boxes, domain II (p*ABI5*-II) covers the fourth and fifth W-boxes, and domain III covers the sixth W-box ([Fig. 5B](#F5){ref-type="fig"}). W-box 3 was not assayed due to a technical difficulty with its isolation ([Fig. 5B](#F5){ref-type="fig"}). It was shown that WRKY18 and WRKY40, but not WRKY60, bind domain I (p*ABI5*-I) and domain II (p*ABI5*-II) ([Fig. 5C](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}), and that WRKY18 and WRKY60, but not WRKY40, bind domain III (p*ABI5*-III) of the *ABI5* promoter ([Fig. 5E](#F5){ref-type="fig"}).

![Interaction of WRKYs with the *ABI5* promoter. (A) Yeast one-hybrid assay. The prey vector harbouring WRKY40, WRKY18, and WRKY60 (indicated by +WRKY40, +WRKY18, and +WRKY60, respectively) and the bait vector pHIS2 harbouring the *ABI5* promoter (indicated by p*ABI5*-pHIS2) were used to co-transform yeast cells. The transformation with empty vector pGADT7 (indicated by +pGADT7) was taken as a negative control. The experiments were repeated three times with the same results. (B) The promoter structure of the *ABI5* gene. W1--W6 denote each W-box numbered from left to right with sequence sites relative to the star code. The top bars with the p*ABI5-*1 to *ABI5-*5 domains indicate the sequence fragments used in the ChIP assay with the antiserum specifically against WRKY40, which was described in a previous report ([@CIT0026]). The bottom bars with the first domain (p*ABI5*-I), second domain (p*ABI5*-II), and third domain (p*ABI5*-III) indicate the sequence fragments used in the GSAs described in (C), (D), and (E). (C) GSA shows that WRKY18, WRKY40, WRKY40 plus WRKY18 (WRKY40+18), WRKY18 plus WRKY60 (WRKY18+60), and WRKY40 plus WRKY60 (WRKY40+60) bind the p*ABI5*-I fragment, but WRKY60 and WRKY40 plus WRKY18 plus WRKY60 (WRKY40+18+60) do not (left panel). The 6×His tag peptide (6His), which was fused to WRKY protein for WRKY protein production, and BSA protein and the promoter fragments harbouring the mutated W-boxes 1 and 2 (W1, W2) or the W1/W2 double mutation, served as negative controls (right panel). W-box mutation at W1: TTGAC→TTCAC, and at W2: GTCAA→CTCAA (see the Materials and methods). The experiments were repeated five times with substantially the same results. (D) GSA shows that WRKY40, WRKY18, WRKY40 plus WRKY18 (WRKY40+18), and WRKY40 plus WRKY60 (WRKY40+60) bind the p*ABI5*-II fragment, but WRKY60, WRKY18 plus WRKY60 (WRKY18+60), and WRKY40 plus WRKY18 plus WRKY60 (WRKY40+18+60) do not (top panel). The 6×His tag peptide (6His), which was fused to WRKY protein for WRKY protein production, and the promoter fragments harbouring the mutated W-box 4 (W4), served as negative controls (bottom panel). W-box mutation at W4: GTCA→GTTA (see the Materials and methods). The experiments were repeated five times with substantially the same results. (E) GSA shows that WRKY18, WRKY60, WRKY40 plus WRKY18 (WRKY40+18), WRKY40 plus WRKY60 (WRKY40+60), and WRKY40 plus WRKY18 plus WRKY60 (WRKY40+18+60) bind the p*ABI5*-III fragment, but WRKY40 and WRKY18 plus WRKY60 (WRKY18+60) do not (top panel). The 6×His tag peptide (6His), which was fused to WRKY protein for WRKY protein production, and BSA protein and the promoter fragments harbouring the mutated W-box 6 (W6), served as negative controls (bottom panel). W-box mutation at W6: GTCAA→CTCAA (see the Materials and methods). The experiments were repeated five times with substantially the same results. In (C), (D), and (E), loading protein amounts were tested by immunoblotting with anti-6His serum and an antiserum specifically against WRKY40 ([@CIT0026]), and relative band intensities, which are normalized relative to the intensity of the loading sample of the assay with WRKY40 alone (indicated by 100), are indicated by numbers above (for 'WRKY40' bands) or below the bands (for 'Ant-6His' bands).](exbotj_ers293_f0005){#F5}

The binding of WRKY18 to domain II disappeared when it was mixed with WRKY60 ([Fig. 5D](#F5){ref-type="fig"}), and binding of WRKY 18 and WRKY60 to domain III disappeared when the two WRKYs were mixed together ([Fig. 5E](#F5){ref-type="fig"}), suggesting a mutual antagonistic effect of WRKY18 and WRKY60 in these binding processes to domains II and III of the *ABI5* promoter. However, WRKY18 and WRKY60 did not show antagonistic interaction in their binding to domain I ([Fig. 5C](#F5){ref-type="fig"}). The mixed proteins WRKY18 plus WRKY40 and WRKY40 plus WRKY60 showed binding activities to all three domains I, II, and III ([Fig. 5C](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}, [5E](#F5){ref-type="fig"}). The mixture of the three WRKYs was shown to bind domain III ([Fig. 1E](#F1){ref-type="fig"}), but not domains I or II ([Fig. 3C](#F3){ref-type="fig"}, [3D](#F3){ref-type="fig"}). These data suggest, as described above for the *ABI4* promoter, that the interactions of the WRKYs with each other affect their binding to the *ABI5* promoter domains.

Neither the binding activity of the WRKYs to the negative control *ABI5* promoter domains harbouring various mutated W-boxes, nor that of 6×His peptide and BSA to any domain of the *ABI5* promoter ([Fig. 5C](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}, [5E](#F5){ref-type="fig"}), was observed, showing that the observed binding activities of the WRKYs were specific. The loading amounts of the different WRKY proteins in the assays, tested by immunoblotting, were shown to be substantially equal for each WRKY protein in the assays with a single WRKY protein, and the amounts were equally doubled in the assays with two WRKY proteins, and tripled with three WRKY proteins, indicating that the loss of binding activities of the different WRKYs or mixtures ([Fig. 5C--E](#F5){ref-type="fig"}) was specific, but was not caused by a possible difference in the protein loading amount.

The above-described binding activity of WRKY18 to all three domains (p*ABI5*-I/II/III) of the *ABI5* promoter and that of WRKY60 to the p*ABI5*-III domain of the *ABI5* promoter ([Fig. 5B--E](#F5){ref-type="fig"}) were confirmed by the ChIP analysis ([Fig. 2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"}; [Supplementary Table S1](http://jxb.oxfordjournals.org/lookup/suppl/doi:10.1093/jxb/ers293/-/DC1) at *JXB* online), revealing that WRKY18 and WRKY60 interact with the *ABI5* promoter *in vivo*.

It is noteworthy that the *in vivo* interaction of WRKY40 with the *ABI5* promoter by the ChIP assay via p*ABI5-*3/4 domains ([@CIT0026]) that cover the p*ABI5*-II domain of the present experiment ([Fig. 5B](#F5){ref-type="fig"}), but not via the p*ABI5-*5 domain ([@CIT0026]) that covers the p*ABI5*-III domain of the present experiment ([Fig. 5B](#F5){ref-type="fig"}), was previously shown, which is consistent with the data of the above-described GSA ([Fig. 5D](#F5){ref-type="fig"}, [5E](#F5){ref-type="fig"}). However, the previous report did not detect any binding activity of WRKY40 to the p*ABI5-*1/2 domains ([@CIT0026]) that cover the present p*ABI5*-I domain ([Fig. 5B](#F5){ref-type="fig"}), which is inconsistent with the data of the above-described GSA ([Fig. 5C](#F5){ref-type="fig"}).These experiments were conducted repeatedly, and the results were confirmed. The reason for this inconsistency is unknown. Nevertheless, the present GSA-detected *in vitro* interaction of WRKY40 with the *ABI5* promoter is essentially consistent with the ChIP-detected *in vivo* data.

Furthermore, using the *in vivo* system by co-transforming tobacco leaves with the *WRKY* genes and the *ABI5* promoter, it was shown that WRKY18 and WRKY40 interacted with the *ABI5* promoter *in vivo*, and inhibited the promoter activity, while WRKY60 showed a reduced *in vivo* effect ([Fig. 6A](#F6){ref-type="fig"}). This is globally consistent with the GSA data in which WRKY60 does not bind two (domain I or II) of the three domains of the promoter ([Fig. 5C](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}). It was further observed that co-expression of WRKY18 and WRKY60 suppressed the repressive effect of WRKY18 on the *ABI5* promoter activity ([Fig. 6B](#F6){ref-type="fig"}), which is consistent with the antagonistic effect of WRKY60 on WRKY18 binding to domains II and III of the *ABI5* promoter observed in the GSA ([Fig. 5D](#F5){ref-type="fig"}, [5E](#F5){ref-type="fig"}). As mentioned above for the *ABI4* promoter ([Fig. 3C](#F3){ref-type="fig"}), co-expression of the three WRKYs completely suppressed the repressive effect of each single WRKY18 or WRKY40 on the *ABI5* promoter activity ([Fig. 6C](#F6){ref-type="fig"}), which is consistent with the inability of the mixture of the three WRKYs to bind domain I or II of the *ABI5* promoter observed in the GSA ([Fig. 5C](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}).

![Test of the interactions of WRKYs with the *ABI5* promoter *in vivo* in tobacco leaves. The tobacco leaves were transformed with the following constructs together with a control construct harbouring the Actin-encoding open reading frame, called 'K': (A) with p*ABI5*-LUC plus K, p*ABI5*-LUC plus WRKY40 and K, p*ABI5*-LUC plus WRKY18 and K, or p*ABI5*-LUC plus WRKY60 and K; (B) with p*ABI5*-LUC plus K, p*ABI5*-LUC plus WRKY40 and WRKY18 and K, p*ABI5*-LUC plus WRKY18 and WRKY60 and K, or p*ABI5*-LUC plus WRKY40 and WRKY60 and K; (C) with p*ABI5*-LUC plus K, or p*ABI5*-LUC plus WRKY40 and WRKY18 and WRKY60 and K; and (D) with p*ABI5*-LUC alone and p*ABI5*-LUC and K (as controls). The prefix 'p' indicates promoter. Left panels in (A), (B), (C). and (D): fluorescence imaging. Right panels in (A), (B), (C), and (D): fluorescence intensities estimated by fluorescence counts. The expression levels of the internal control Actin protein (K) and the Myc-tagged WRKY18/WRKY40/WRKY60 protein were assayed by immunoblotting with the antiserum against Actin and anti-Myc serum, respectively, and are displayed below the fluorescence counts columns. Relative protein band intensities, which are normalized relative to the intensity of the sample from no-transgenic portions (NT) of the same transgenic leaves for K (Actin), or to that of the p*ABI5*-WRKY40 treatment (A) or p*ABI5*-WRKY40+18 treatment (B), are indicated by numbers below the bands. Each value for the columns in the right panels is the mean ±SE of five independent determinations, and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test).](exbotj_ers293_f0006){#F6}

In the internal controls, it was observed that the Actin2 protein with the *ABI5* promoter--LUC and/or with the WRKYs co-expressed in a substantially equal amount did not change the activity of the *ABI5* promoter--LUC ([Fig. 6D](#F6){ref-type="fig"}) or any observations ([Fig. 6A--C](#F6){ref-type="fig"}), and the expression levels of each WRKY protein, assayed by immunoblotting with the antiserum against their Myc tag, showed no significant difference among them in any assay ([Fig. 6A](#F6){ref-type="fig"}, [6B](#F6){ref-type="fig"}), indicating that the observed differences in the fluorescence intensity were not caused by possible differences in the WRKY levels. These controls showed that the observations of these WRKY--*ABI5* promoter interaction assays are specific and reliable. It was further shown that WRKY18, WRKY40, and WRKY60 did not inhibit the activity of the *ABI5* promoter harbouring W-box 1, 2, and 4 triple mutations ([Fig. 4B](#F4){ref-type="fig"}), revealing that the WRKY proteins bind the *ABI5* promoter through the W-box motif.

Disruption of WRKY18, WRKY40, or WRKY60 enhances *ABI4* or *ABI5* expression in germinating seeds {#s15}
-------------------------------------------------------------------------------------------------

It was previously shown that, in 2-week-old seedlings, disruption of either *WRKY18* or *WRKY40* decreased *ABI4* expression, but increased *ABI5* expression, and disruption of both the *WRKY* genes increased expression of both *ABI4* and *ABI5*, while disruption of *WRKY60* increased *ABI4* expression, but decreased *ABI5* expression ([@CIT0026]). Given that *ABI4* and *ABI5* are mainly expressed in early developmental processes and regulate seed germination and post-germination growth ([@CIT0014]; [@CIT0012]), the expression levels of these two genes were tested in germinating seeds of different *wrky* mutants 36h and 90h after stratification. The results showed that the expression levels of both *ABI4* and *ABI5* increased in the *wrky40* single mutant and the *wrky18 wrky40* and *wrky18 wrky60* double mutants in comparison with those in wild-type plants at both 36h and 90h after stratification ([Fig. 7](#F7){ref-type="fig"}). The data in the *wrky18 wrky40* double mutant and those regarding *ABI5* expression in the *wrky40* mutant are consistent with those obtained in 2-week-old mutant plants ([@CIT0026]), but the up-regulation of *ABI4* expression in the *wrky40* mutant was not observed in the 2-week-old mutant plants, in which *ABI4* was down-regulated ([@CIT0026]) as mentioned above. In the *wrky18* single mutant and *wrky18 wrky40 wrky60* triple mutant, expression of *ABI5* increased, but that of *ABI4* was not significantly affected at both 36h and 90h after stratification ([Fig. 7](#F7){ref-type="fig"}). In contrast, in the *wrky60* single mutant and *wrky40 wrky60* double mutant, expression of *ABI4* increased at both 36h and 90h after stratification, but that of *ABI5* was not significantly affected at 36h after stratification; however, at 90h after stratification, *ABI5* was up-regulated in the two mutants ([Fig. 7](#F7){ref-type="fig"}). The data regarding *ABI4* expression in the *wrky60* mutant and *ABI5* expression in the *wrky18* mutant are consistent with those obtained in 2-week-old mutant plants ([@CIT0026]), but *ABI4* in the *wrky18* mutant and *ABI5* in the *wrky60* mutant were shown to be down-regulated in the 2-week-old mutant plants ([@CIT0026]), which is different from the expression levels in the germinating seeds ([Fig. 7](#F7){ref-type="fig"}). These findings showed that the regulation of expression of *ABI4* and *ABI5* by the three WRKY transcription factors is developmental stage dependent. Previous reports did not observe differences in *ABI4* and *ABI5* expression in the *wyky18* mutant in 5-week-old mature plants ([@CIT0019]; [@CIT0031]), suggesting that WRKY18 (or also the other two WRKYs) does not function in the regulation of these two ABA-related genes during late developmental stages, which is consistent with the very early expression profile of *ABI4* and *ABI5* mainly in germinating seeds and young seedlings (1--5 d after stratification; [@CIT0014]; [@CIT0012]; [@CIT0018]) and with the present observations that the three WRKYs function to regulate early developmental processes including seed germination and early seedling growth in response to ABA.

![Expression of *ABI4* and *ABI5* in the *wrky* mutants. The germinating seeds were sampled at 36h and 90h after stratification to assay expression of *ABI4* (top panels) and *ABI5* (bottom panels) in the *wrky* single, double (*wrky40 wrky18*, *wrky18 wrky60*, and *wrky40 wrky 60*), and triple (*wrky40 wrky18 wrky60*) mutants by quantitative real-time PCR. Each value is the mean ±SE with five independent determinations, and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test).](exbotj_ers293_f0007){#F7}

Introduction of the *abi4* or *abi5* mutation into the *wrky18* and *wrky60* mutants suppresses ABA hypersensitivity of these mutants {#s16}
-------------------------------------------------------------------------------------------------------------------------------------

It was previously reported that WRKY40 functions directly upstream of ABI5 and also probably upstream of ABI4 in ABA signalling ([@CIT0026]), but it remains unclear whether WRKY18 and WRKY60 cooperate with WRKY40 to regulate ABA signalling upstream of ABI4 and ABI5. In the present experiment, it was first confirmed that the null mutation in the *WRKY18* or *WRKY60* gene results in ABA-hypersensitive phenotypes in seed germination and post-germination growth, though the ABA-hypersensitive phenotypes are weaker in the *wrky60* mutant than in the *wrky18* mutant ([Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}). The *wrky60* mutant showed wild-type ABA responses sometimes, especially at higher ABA concentrations for seed germination ([Fig. 8C](#F8){ref-type="fig"}, [8D](#F8){ref-type="fig"}) or at lower ABA concentrations for post-germination growth ([Fig. 9C](#F9){ref-type="fig"}, [9D](#F9){ref-type="fig"}), but in no case did this mutant show ABA-insensitive phenotypes. The ABA-hypersensitive phenotypes of the *wrky18* mutant were virtually always significant ([Figs 8A](#F8){ref-type="fig"}, [8B](#F8){ref-type="fig"}, [9A](#F9){ref-type="fig"}, [B](#F8){ref-type="fig"}, [10](#F10){ref-type="fig"}). It is noteworthy that post-germination growth was assayed with two different systems: one in which the seeds were directly planted in ABA-containing medium, and post-germination growth was investigated 7 d after stratification ([Fig. 9](#F9){ref-type="fig"}), and another system in which the germinating seeds were transferred \~46h after stratification from ABA-free medium to ABA-containing medium, and post-germination growth was recorded 10 d after the transfer ([Fig. 10](#F10){ref-type="fig"}). Substantially the same results of ABA-hypersensitive phenotypes in post-germination growth were obtained with these two systems for both *wrky18* and *wrky60* mutants ([Figs 9](#F9){ref-type="fig"}, [10](#F10){ref-type="fig"}). These data verify previous observations that both WRKY18 and WRKY60 negatively regulate ABA signalling ([@CIT0026]), and support the notion that WRKY60 balances the negative roles of WRKY18 and WRKY40 in ABA signalling.

![The *abi4* and *abi5* mutations suppress ABA-hypersensitive phenotypes of the *wrky18* and *wrky60* mutants in ABA-induced seed germination inhibition. Seed germination rate of the wild-type plants (Col) and mutants *abi4*, *wrky18*, and *abi4 wrky18* (A), *abi5*, *wrky18*, and *abi5 wrky18* (B), *abi4*, *wrky60*, and *abi4 wrky60* (C), or *abi5*, *wrky60*, and *abi5 wrky60* (D) was recorded in ABA-free medium (0 µM ABA) and ABA-containing medium (0.5, 1, and 3 µM) from 48h to 72h after stratification. Each value is the mean ±SE of five independent biological determinations and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test) when comparing values within the same ABA concentration and the same time point after stratification.](exbotj_ers293_f0008){#F8}

![The *abi4* and *abi5* mutations suppress ABA-hypersensitive phenotypes of the *wrky18* and *wrky60* mutants in ABA-induced post-germination arrest assessed by planting seeds directly in ABA-containing medium. Post-germination growth of the wild-type plants (Col) and mutants *abi4*, *wrky18* (*w18*), and *abi4 wrky18* (*18 i4*) (A), *abi5*, *wrky18* (*w18*), and *abi5 wrky18* (*18 i5*) (B), *abi4*, *wrky60* (*w60*), and *abi4 wrky60* (*60 i4*) (C), or *abi5*, *wrky60* (*w60*), and *abi5 wrky60* (*60 i5*) (D) was recorded in ABA-free medium (0 µM ABA, as indicated at the bottom) and ABA-containing medium (0.3 µM and 0.6 µM, as indicated at the bottom) 7 d after stratification. The right panels (columns) show corresponding statistical data of the root length of these mutants, in which each value is the mean ±SE of five independent biological determinations and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test) when comparing values within the same ABA concentration.](exbotj_ers293_f0009){#F9}

![The *abi4* and *abi5* mutations suppress ABA-hypersensitive phenotypes of the *wrky18* and *wrky60* mutants in ABA-induced post-germination arrest assessed by transferring germinating seeds 48h after stratification from ABA-free medium to ABA-containing medium. Post-germination growth of the wild-type plants (Col) and mutants *abi4*, *wrky18* (*w18*), and *abi4 wrky18* (*18 i4*) (A), *abi5*, *wrky18* (*w18*), and *abi5 wrky18 (18 i5*) (B), *abi4*, *wrky60* (*w60*), and *abi4 wrky60* (*60 i4*) (C), or *abi5*, *wrky60* (*w60*), and *abi5 wrky60* (*60 i5*) (D) was recorded in ABA-free medium (0 µM ABA, as indicated at the bottom) and ABA-containing medium (1 µM, as indicated at the bottom) 10 d after stratification. The right panels (columns) show corresponding statistical data of the root length of these mutants, in which each value is the mean ±SE of five independent biological determinations and different letters indicate significant differences at *P* \< 0.05 (Duncan's multiple range test) when comparing values within the same ABA concentration.](exbotj_ers293_f0010){#F10}

The *abi4 wrky18* and *abi4 wrky60* double mutants showed substantially the same intensities of ABA-insensitive phenotypes as those in the *abi4* single mutant, and the *abi5 wrky18* and *abi5 wrky60* double mutants as those of the *abi5* single mutant, in ABA-induced seed germination inhibition ([Fig. 8A--D](#F8){ref-type="fig"}) and post-germination growth arrest ([Figs 9A--D](#F9){ref-type="fig"}, [10A--D](#F10){ref-type="fig"}), which provides genetic evidence that ABI4 and ABI5 function downstream of WRKY18 and WRKY60 in ABA signalling, consistent with the idea that ABI4 and ABI5 are the targets of these two WRKY transcription factors.

Discussion {#s17}
==========

WRKY18 and WRKY60 target *ABI4* and *ABI5* genes in the ABA signalling pathway {#s18}
------------------------------------------------------------------------------

Although it was previously demonstrated that WRKY40 functions in ABA signalling by repressing the *ABI5* gene and interacting with the *ABI4* gene ([@CIT0026]), it has been unclear whether its two paralogues, WRKY18 and WRKY60, target the *ABI4* and *ABI5* genes. In the present study, this question was answered by providing evidence that *ABI4* and *ABI5* are downstream targets of these two WRKY transcription factors to regulate ABA signalling. First, it was shown that WRKY18 and WRKY60 proteins interact with the W-box in the promoters of the *ABI4* and *ABI5* genes, as evidenced by yeast one-hybrid assay, GSA, and ChIP analysis ([Figs 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [5](#F5){ref-type="fig"}). Secondly, WRKY18 and WRKY60 were shown to inhibit the expression of the *ABI5* gene, and WRKY60 inhibits the expression of the *ABI4* gene, as evidenced by both the *in vivo* assay of co-expression of the WRKYs with the *ABI4* and *ABI5* promoters ([Figs 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}) and expression analysis of *ABI4* and *ABI5* in various *wrky* mutants ([Fig. 7](#F7){ref-type="fig"}), which is consistent with their negative roles in ABA signalling. Finally, genetic evidence was provided that the mutations of *ABI4* and *ABI5* suppress ABA-hypersensitive phenotypes of the null mutant alleles of *WRKY18* and *WRKY60* genes ([Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}), demonstrating that ABI4 and ABI5 function downstream of these two WRKY transcription factors in ABA signalling.

As regards the negative roles of WRKY18 and WRKY60 in ABA signalling, it is noteworthy that, in a previous report, the *wrky40* single mutant and *wrky40 wrky18* double mutant were shown to display ABA-hypersensitive phenotypes ([@CIT0005]), which is consistent with the present ([Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}) and previous observations ([@CIT0026]). However, Chen and co-workers showed that the *wrky18* and *wrky60* single mutants and *wrky18 wrky60* double mutants displayed ABA-insensitive phenotypes in seed germination and post-germination growth, and the *wrky40 wrky60* double mutant showed ABA insensitivity in seed germination but a wild-type ABA response in post-germination growth ([@CIT0005]). These data suggest the possible positive roles of WRKY18 and WRKY40 in ABA signalling ([@CIT0005]), which is inconsistent with the present ([Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}) and previous observations ([@CIT0026]). In the present experiment with considerable biologically independent repetitions, previously reported data ([@CIT0026]) showing that null mutation of either *WRKY18* or *WRKY60*, like null mutation of *WRKY40*, results in ABA hypersensitivity, but not ABA insensitivity, in ABA-induced seed germination inhibition and post-germination growth arrest were reproduced well ([Figs. 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}).

These discrepancies are probaly due to weak ABA-related phenotypes of the *wrky18* and *wrky60* mutants, which may be affected more easily by environmental conditions. It was previously shown that the double mutant *wrky40 wrky18* displayed the strongest ABA-hypersensitive phenotypes, which was followed by the *wrky40* single mutant, and that the *wrky18* and *wrky60* mutants showed relatively weaker ABA-hypersensitive phenotypes ([@CIT0026]). This may partly explain why the ABA-hypersensitive phenotypes of the *wrky40* single and *wrky18 wrky40* double mutants were, but those of the *wrky18*, *wrky60*, and relative double mutants were not, detected by [@CIT0005]. The weak ABA-related phenotypes of the *wrky18* and *wrky60* mutants may be due to antagonistic effects of different WRKY members (as described in the present experiment) on the one hand, and, on the other, may probably be explained by functional redundancy, because multiple WRKY transcription factors are involved in ABA signalling as negative regulators ([@CIT0026]). For instance, in addition to WRKY40 ([@CIT0005]; [@CIT0026]), two other reports have identified WRKY2 and WRKY63 as further transcription repressors in ABA signalling ([@CIT0016]; [@CIT0021]). The different environmental conditions may have an impact on the weak phenotypes of ABA sensitivity of the *wrky18* and *wrky60* mutants, thus possibly creating the discrepancies. In this regard, the seed storage conditions may also be of importance for showing proper phenotypes, and non-optimal storage conditions of seeds may affect the investigation of ABA sensitivity.

Additionally and importantly, it was noted that Chen and co-workers transferred 4-day-old seedlings from ABA-free medium to 2 µM ABA-containing medium to assay post-germination growth in response to ABA ([@CIT0005]), which is differentt from the techniques used in this study where the assays was performed by directly planting seeds in ABA-containing medium (ABA concentrations \<0.7 µM) or transferring the germinating seeds to ABA-containing medium (ABA concentrations \<1--2 µM) 46--48h (but not 4 d) after stratification. In the latter system, the early transfer (\<48h after stratification) of germinating seeds to ABA-containing medium is important for assaying ABA responses of these *wrky* mutants, because the ABA-related phenotypes disappeared when the transfer was carried out \>48h after stratification. In contrast to the observations described in the previous report ([@CIT0005]), in the conditions used in the present study, ABA-insensitive phenotypes were never observed in these *wrky* mutants when seedlings were transferred 4 d after stratification from ABA-free to 2 µM ABA-containing medium, and ABA-hypersensitive phenotypes even disappeared except for the *wrky40* and *wrky40 wrky18* mutants that showed weakly ABA-hypersensitive phenotypes (data not shown). The same phenomenon of this short developmental window (\~48h) of the ABA response as observed in the present ([Figs 9](#F9){ref-type="fig"}, [10](#F10){ref-type="fig"}) and previous assays ([@CIT0026]) was also described by an independent group for the *wrky2* ABA-hypersensitive mutant in ABA-induced post-germination growth arrest ([@CIT0016]). This may be due to a post-germination developmental arrest checkpoint mediated by temporal expression of *ABI5* ([@CIT0018]), which may be a central player downstream of these WRKYs.

Taken together, previous ([@CIT0026]) and present biochemical and genetic experiments consistently demonstrate that the WRKY18 and WRKY60 transcription factors, cooperatively working with WRKY40, inhibit expression of two important, positive ABA signalling components, ABI4 and ABI5, and thus are negatively involved in the ABA signalling pathway.

How do WRKY18, WRKY40, and WRKY60 transcription factors cooperate to repress *ABI4* and *ABI5* genes? {#s19}
-----------------------------------------------------------------------------------------------------

It has been known that one single WRKY may function in the cell signalling process as a negative or positive regulator, the underlying mechanisms of which may involve complex autoregulation or cross-regulation via protein-- protein interaction ([@CIT0009]; [@CIT0033]; [@CIT0010]; [@CIT0020]; [@CIT0006]; [@CIT0022], [@CIT0024]). Consistently, in the current experiments, it was shown, through biochemical and genetic experiments, that WRKY18, like WRKY40, represses the *ABI5* gene as one of the key regulators ([Figs 1](#F1){ref-type="fig"}--[7](#F7){ref-type="fig"}, and for WRKY40, see also [@CIT0026]), and that WRKY60 plays essentially an antagonistic role to balance the functions of WRKY18 and WRKY40 in binding of the *ABI4* and *ABI5* promoters and inhibiting the expression of *ABI4* and *ABI5* genes ([Figs 1](#F1){ref-type="fig"}--[7](#F7){ref-type="fig"}), though WRKY60 itself is a repressor of *ABI4* and *ABI5* genes ([Figs 3](#F3){ref-type="fig"}, [7](#F7){ref-type="fig"}) and functions genetically as a weakly negative regulator of ABA signalling ([Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}, and see also [@CIT0026]). The expression level of *WRKY60* was previously shown to be low ([@CIT0027]; [@CIT0031]), which, however, suggests that the functional WRKY40 and WRKY18 are of special importance for plant development and the proper response to environmental challenges such that their antagonists such as WRKY60 should be repressed. Interestingly, however, the regulation of *ABI4* and *ABI5* expression involves much more complex interactions of the three WRKYs with each other ([Figs 1](#F1){ref-type="fig"}--[7](#F7){ref-type="fig"}), in which one WRKY may play either an agonistic or antagonistic role to other WRKYs in different situations. For instance, WRKY18 antagonizes WRKY40 in the *in vivo* tested expression of the *ABI4* gene ([Fig. 3B](#F3){ref-type="fig"}), whereas WRKY18 aids WRKY40 in repressing both *ABI4* and *ABI5* genes *in planta* ([Fig. 7](#F7){ref-type="fig"}); and the repressive effects of a single WRKY on the promoter binding ([Figs 1](#F1){ref-type="fig"}, [5](#F1){ref-type="fig"}) and expression ([Figs 3](#F3){ref-type="fig"}, [6](#F3){ref-type="fig"}) of *ABI4* and *ABI5* genes may be completely abolished when the three WRKYs meet together.

Synthesizing the experimental data of the promoter binding ([Figs 1](#F1){ref-type="fig"}, [5](#F5){ref-type="fig"}) and expression analysis in the *in vivo* systems ([Figs 2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}) and especially *in planta* expression analysis in various *wrky* mutants ([Fig. 7](#F7){ref-type="fig"}), a working model is proposed of cooperation of the three WRKYs, which bind to different domains of the *ABI4* and *ABI5* promoters ([Fig. 11A](#F11){ref-type="fig"}, [11B](#F11){ref-type="fig"}), in repressing *ABI4* and *ABI5* expression ([Fig. 11C](#F11){ref-type="fig"}, [11D](#F11){ref-type="fig"}). In this model, expression of *ABI4* and *ABI5* may be regulated by different mechanisms. For the *ABI4* gene, the WRKY40 and WRKY60 transcription factors repress its expression, while the mutual antagonistic effects occur between WRKY40 and WRKY60, and WRKY18 antagonizes WRKY40 to balance the repressive functions on the *ABI4* gene ([Fig. 11C](#F11){ref-type="fig"}). For the *ABI5* gene, however, the two WRKYs, WRKY18 and WRKY40, work alone or together to repress *ABI5*, and WRKY60 represses *ABI5* but at the same time antagonizes the repressive effect of WRKY18 and the WRKY18--WRKY40 heterodimer to balance the repressive effects on the *ABI5* gene ([Fig. 11D](#F11){ref-type="fig"}).

![Proposed working model of cooperation of three WRKYs in repressing *ABI4* and *ABI5* expression. (A and B) Different binding domains of the three WRKY transcription factors WRKY18 (indicated by 18), WRKY40 (indicated by 40), and WRKY60 (indicated by 60) in the *ABI4* (A) and *ABI5* (B) promoters. I, II, and III denote each domain numbered from left to right with sequence sites relative to the star code. The question mark indicates an as not yet determined WRKY40-binding domain (red) or a W-box that was not tested for WRKY binding (blue). (C and D) Working models of the cooperation of three WRKYs in repressing *ABI4* (C) and *ABI5* (D) expression. (C) WRKY40 and WRKY60 transcription factors repress *ABI4* expression, while mutual antagonistic effects occur between WRKY40 and WRKY60, and WRKY18 antagonizes WRKY40 to balance the repressive functions on the *ABI4* gene. (D) The two WRKYs, WRKY18 and WRKY40, work alone or together to repress *ABI5* expression, and WRKY60 represses *ABI5* but at the same time antagonizes the repressive effect of WRKY18 and the WRKY18--WRKY40 heterodimer to balance the repressive effects on the *ABI5* gene. See the text for detailed explanation.](exbotj_ers293_f0011){#F11}

This model may partly explain the expression profile of *ABI4* and *ABI5* genes in *wrky* mutants ([Fig. 7](#F7){ref-type="fig"}) and the ABA-hypersensitive phenotypes of these *wrky* mutants ([Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}, and see also [@CIT0026]), which is summarized in [Fig. 12](#F12){ref-type="fig"}. Disruption of WRKY18 and WRKY40 in the *wrky18 wrky40* double mutant derepresses expression of both the *ABI4* and *ABI5* genes to the greatest degree, given that WRKY60 alone present in this mutant has no substantial repressive effect on the *ABI5* gene and a weaker repressive effect on the *ABI4* gene. It is noteworthy that loss of function of WRKY18 and WRKY40 may probably also induce other unknown processes to stimulate *ABI4* and *ABI5* expression. The *wrky40* mutant follows the *wrky18 wrky40* double mutant in terms of its higher expression levels of both *ABI4* and *ABI5* genes, because *ABI5* is, and *ABI4* is partly, derepressed according to the working model. After the *wrky40* mutant, it is interesting to note that the *wrky18 wrky40 wrky60* triple mutant has the highest *ABI5* level like the *wrky18 wrky40* double mutant, but a wild-type low level of *ABI4*. This is essentially consistent with its intensity of ABA hypersensitivity, which follows that of the *wrky18 wrky40* double mutant and the *wrky40* single mutant ([@CIT0026]). The low *ABI4* level in the triple mutant may be explained by a complex negative feedback mechanism of the high *ABI5* level on *ABI4* expression, which may involve other unknown factors when none of the three WRKY transcription repressors is present. These unknown factors may be, for example, WRKY2 and/or WRKY63, which may act both upstream and downstream of ABI4 and ABI5 ([@CIT0016]; [@CIT0021]; [@CIT0024]), and may repress the *ABI4* gene in this situation of a high *ABI5* level due to loss of function of the three WRKY repressors. This negative feedback loop of the WRKY members on the *ABI4* and *ABI5* genes (WRKY18/40/60--ABI5--WRKY2/63--ABI4) may also exist in other *wrky* mutants and the wild-type plants: the feedback effect of WRKY18/40/60-dependent *ABI5* repression on *ABI4* could partly explain the observations that the expression level of *ABI4* tends to be higher when the *ABI5* level is lower ([Figs 7](#F7){ref-type="fig"}, [12](#F12){ref-type="fig"}).

![The models to explain ABA sensitivities and expression levels of *ABI4* and *ABI5* genes in different *wrky* mutants. 'ABA sensitivity' indicates the intensity of the ABA-hypersensitive phenotypes of different *wrky* mutants in comparison with wild-type plants as described in the present study and a previous report ([@CIT0026]); the larger red area indicates higher ABA sensitivity (stronger ABA-hypersensitive phenotype); the blue area indicates wild-type ABA sensitivity in seed germination and post-germination growth. '*ABI5* level' and '*ABI4* level' indicate the approximate averages (at 36h and 90h after stratification) of the expression levels of these two genes in the different *wrky* mutants as described in the present experiment in [Fig. 7](#F7){ref-type="fig"}. In the *wrky18 wrky40 wrky60* triple mutant, a negative feedback mechanism of the high *ABI5* level on *ABI4* is postulated to explain the low *ABI4* expression, which is mediated by additional, unknown factors (indicated by a question mark). See the text for a detailed explanation.](exbotj_ers293_f0012){#F12}

*ABI4* and *ABI5* expression in other *wrky* mutants (*wrky18*, *wrky60*, *wrky18 wrky60*, and *wrky40 wrky60*) may also be partly explained by this model. However, much more complex mechanisms than this simplified model concerning mainly post-translational interaction of the three WRKYs must be involved in the regulation of expression of *ABI4* and *ABI5*, where the three WRKYs and even WRKY2 and WRKY63 may constitute only one part of the entire network. First, and most importantly, the three WRKY transcription factors may repress expression of their own encoding genes by auto- and/or cross-regulation ([@CIT0020]; [@CIT0019]), and so up- or down-regulation of any of the three WRKYs may induce a feedback regulation of its own gene and the two other genes. Secondly, in addition to the three members of the WRKY transcription factor superfamily, other WRKY members and other classes of transcription factors must participate in this transcription regulation. As mentioned above, two examples are WRKY2 and WRKY63 ([@CIT0016]; [@CIT0021]; [@CIT0024]), which may potentially cross-talk with WRKY18, WRKY40, and WRKY60 to mediate ABA signalling upstream of ABI4 and ABI5. Thirdly, the WRKY18 and/or WRKY40 transcription factors are involved in many other signalling processes such as reactive oxygen species, cytokinin, salicylic acid, ethylene, and jasmonic acid signalling, through which the WRKYs may regulate ABA-related genes ([@CIT0019]; [@CIT0002]; [@CIT0031]). Finally, WRKYs may regulate gene expression by complex mechanisms by acting on chromatin remodelling, interacting with small RNA, and even preparing the promoter for activation or repression ([@CIT0029]; [@CIT0020]). Therefore, it is most likely that the highly complex mechanisms as described above may interact to form a regulation network to determine the expression of ABA-related genes such as *ABI4* and *ABI5*, in which the three WRKY transcription factors may participate to constitute a key step. In this transcriptional regulation network, disruption of any of the three WRKYs may induce complex feedback or feed-forward consequences.

Additionally, it is noteworthy that ABI4 was reported to act upstream of ABI5 ([@CIT0003]) or possibly to function in a different pathway from that of ABI5 in ABA signalling ([@CIT0021]). Therefore, the transcriptional regulation of *ABI5* by WRKY40/60 may be realized to some extent indirectly through regulation of *ABI4* by these WRKYs. The function of ABI4 was shown to be independent of WRKY63/ABO3 ([@CIT0021]), suggesting that, while probably sharing ABI5 as a common downstream target, the WRKY18/40/60-mediated signalling may be partly different from the WRKY63-mediated signalling, which may diverge at ABI4 from each other. These findings also suggest that ABI5 is likely to be a common and central player downstream of the WRKYs at least including WRKY18, WRKY40, WRKY60, and WRKY63.

Consistently, the intensities of the ABA-hypersensitive phenotypes of the *wrky* mutants, which were described in a previous report ([@CIT0026]) and in the present experiments (*wrky18* and *wrky60* mutants, see [Figs 8](#F8){ref-type="fig"}--[10](#F10){ref-type="fig"}), may be partly explained by the expression levels of *ABI5* ([Fig. 10](#F10){ref-type="fig"}). However, the expression level of *ABI4*, which tends to be higher when the *ABI5* level is lower, is generally not correlated with the ABA sensitivities of the *wrky* mutants except for the *wrky18 wrky40* double mutant that shows the highest *ABI4* level with the highest ABA sensitivity. Particular exceptions are the *wrky18 wrky60* and *wrky40 wrky60* double mutants: the former shows higher expression levels of both *ABI4* and *ABI5*, and the latter has the same levels of *ABI4* and *ABI5* as the *wrky60* ABA-hypersensitive mutant, but both mutants show a wild-type ABA response, which, however, supports the function of WRKY60 as a central balancer of WRKY18 and WRKY40. Overall, the present observations are consistent with the idea that the three WRKYs function by targeting far more genes than *ABI4* and *ABI5* to regulate ABA signalling ([@CIT0026]), in which ABI5 may be a central player among these downstream targets, and ABI4 plays a role supplementary to ABI5. Further identification of new ABA signalling WRKY members and their downstream targets will be needed in the future to understand the complex mechanisms of the WRKY-mediated ABA signalling pathway.

Supplementary data
==================

Supplementary data are available at *JXB* online.

[Figure S1.](http://jxb.oxfordjournals.org/lookup/suppl/doi:10.1093/jxb/ers293/-/DC1) Purification of the *E. coli*-expressed WRKY18, WRKY40, and WRKY60 proteins from *E. coli* extracts.

[Table S1.](http://jxb.oxfordjournals.org/lookup/suppl/doi:10.1093/jxb/ers293/-/DC1) Information for detecting the WRKY18-, WRKY40-, and WRKY60-binding promoter sequences by PCR in the chromatin co-immunoprecipitation (ChIP) assay with the antibody against GFP and by gel shift assay (GSA).
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